| Literature DB >> 30766437 |
Yong Chon Park1, Min-Soo Lee2, Tian-Mei Si3, Helen F K Chiu4, Shigenobu Kanba5, Mian-Yoon Chong6, Adarsh Tripathi7, Pichet Udomratn8, Kok Yoon Chee9, Andi J Tanra10, Golam Rabbani11, Afzal Javed12, Samudra Kathiarachchi13, Win Aung Myint14, Tran Van Cuong15, Kang Sim16, Shu-Yu Yang17, Norman Sartorius18, Chay-Hoon Tan19, Naotaka Shinfuku20, Seon-Cheol Park21.
Abstract
BACKGROUND: Although disorganized speech is seen as one of the nuclear features of schizophrenia, there have been few reports of disorganized speech-associated psychotropic drug-prescribing patterns in large samples of schizophrenia patients.Entities:
Keywords: Asian; Disorganized speech; Mood stabilizers; Schizophrenia
Year: 2018 PMID: 30766437 PMCID: PMC6362172 DOI: 10.1016/j.jsps.2018.11.006
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
Baseline and psychopathological characteristics of schizophrenia patients with and without disorganized speech.
| Total sample (n = 3744) | Disorganized speech | Statistical coefficient | |||
|---|---|---|---|---|---|
| Present (n = 1110) | Absent (n = 2634) | ||||
| Age, mean (SD) years | 39.5 (13.1) | 38.6 (12.7) | 39.9 (13.3) | t = −2.653 | 0.008 |
| Men, n (%) | 2199 (58.7) | 641 (57.7) | 1558 (59.1) | χ2 = 0.633 | 0.426 |
| Country/area | χ2 = 532.723 | <0.0001 | |||
| Bangladesh, n (%) | 99 (2.6) | 77 (6.9) | 22 (0.8) | ||
| China, n (%) | 160 (4.3) | 29 (2.6) | 131 (5.0) | ||
| Hong Kong, n (%) | 31 (0.8) | 9 (0.8) | 22 (0.8) | ||
| India, n (%) | 479 (12.8) | 97 (8.7) | 382 (14.5) | ||
| Indonesia, n (%) | 581 (15.5) | 143 (12.9) | 438 (16.6) | ||
| Japan, n (%) | 229 (6.1) | 67 (6.0) | 162 (6.2) | ||
| Korea, n (%) | 131 (3.5) | 16 (1.4) | 115 (4.4) | ||
| Malaysia, n (%) | 305 (8.1) | 62 (5.6) | 243 (9.2) | ||
| Myanmar, n (%) | 164 (4.4) | 67 (6.0) | 97 (3.7) | ||
| Pakistan, n (%) | 298 (8.0) | 191 (17.2) | 107 (4.1) | ||
| Singapore, n (%) | 171 (4.6) | 48 (4.3) | 123 (4.7) | ||
| Sri Lanka, n (%) | 97 (2.6) | 15 (1.4) | 82 (3.1) | ||
| Taiwan, n (%) | 403 (10.8) | 82 (7.4) | 321 (12.2) | ||
| Thailand, n (%) | 322 (8.6) | 46 (4.1) | 276 (10.5) | ||
| Viet Nam, n (%) | 274 (7.3) | 161 (14.5) | 113 (4.3) | ||
| Regional classification | χ2 = 73.674 | <0.0001 | |||
| Eastern Asia, n (%) | 954 (25.5) | 203 (18.3) | 751 (28.5) | ||
| Southeastern Asia, n (%) | 1817 (48.5) | 527 (47.5) | 1290 (49.0) | ||
| Southern Asia, n (%) | 973 (26.0) | 380 (34.2) | 593 (22.5) | ||
| Income group | χ2 = 138.878 | <0.0001 | |||
| High income, n (%) | 965 (25.8) | 222 (20.0) | 743 (28.2) | ||
| Upper middle income, n (%) | 787 (21.0) | 137 (12.3) | 650 (24.7) | ||
| Lower middle income, n (%) | 1992 (53.2) | 751 (35.7) | 1241 (47.1) | ||
| Inpatient, n (%) | 1951 (52.1) | 832 (75.0) | 1119 (42.5) | χ2 = 329.956 | <0.0001 |
| Duration of illness | χ2 = 9.157 | 0.165 | |||
| <3 month, n (%) | 161 (4.3) | 34 (3.1) | 127 (4.8) | ||
| 3–6 months, n (%) | 125 (3.3) | 34 (3.1) | 91 (3.5) | ||
| 6 months–1 year, n (%) | 199 (5.3) | 65 (5.8) | 134 (5.1) | ||
| 1–5 years, n (%) | 794 (21.2) | 249 (22.4) | 545 (20.7) | ||
| 5–10 years, n (%) | 729 (19.5) | 213 (19.2) | 516 (19.6) | ||
| 10–20 years, n (%) | 971 (25.9) | 278 (25.0) | 693 (26.3) | ||
| >20 years, n (%) | 765 (20.4) | 237 (21.4) | 528 (20.0) | ||
| Delusions, n (%) | 1599 (42.7) | 658 (59.3) | 941 (35.7) | χ2 = 177.065 | <0.0001 |
| Hallucinations, n (%) | 1752 (46.8) | 680 (61.3) | 1072 (40.7) | χ2 = 132.621 | <0.0001 |
| Disorganized behaviors, n (%) | 666 (17.8) | 392 (35.3) | 274 (10.4) | χ2 = 331.421 | <0.0001 |
| Negative symptoms, n (%) | 1313 (35.1) | 429 (38.6) | 884 (33.6) | χ2 = 8.876 | 0.003 |
| Social or occupational dysfunction, n (%) | 1693 (45.2) | 708 (63.8) | 985 (37.4) | χ2 = 219.518 | <0.0001 |
| Verbal aggression, n (%) | 942 (25.2) | 475 (42.8) | 467 (17.7) | χ2 = 260.511 | <0.0001 |
| Physical aggression, n (%) | 780 (20.8) | 429 (38.6) | 351 (13.3) | χ2 = 303.619 | <0.0001 |
| Significant affective symptoms, n (%) | 425 (11.4) | 156 (14.1) | 269 (10.2) | χ2 = 11.452 | 0.001 |
According to the United Nations classification: Eastern Asia (China, Hong Kong, Japan, Korea and Taiwan), Southern Asia (Bangladesh, India, Pakistan and Sri Lanka) and Southeastern Asia (Indonesia, Malaysia, Myanmar, Singapore, Thailand and Viet Nam).
According to the World Bank list of economies: high income (Hong Kong, Japan, Korea, Singapore and Taiwan), upper middle income (China, Malaysia, and Thailand) and Lower middle income (Bangladesh, India, Indonesia, Myanmar, Pakistan, Sri Lanka and Viet Nam).
Psychotropic drug prescribing patterns for schizophrenia patients with and without disorganized speech.
| Total sample (n = 3744) | Disorganized speech | Statistical coefficient | Unadjusted | Adjusted | ||
|---|---|---|---|---|---|---|
| Present (n = 1110) | Absent (n = 2634) | |||||
| Antipsychotic polypharmacy, n (%) | 1597 (42.6) | 556 (50.1) | 1041 (39.5) | χ2 = 35.658 | <0.0001 | 0.006 |
| Long-acting injectable antipsychotics, n (%) | 659 (17.6) | 200 (18.0) | 459 (17.4) | χ2 = 0.189 | 0.664 | 0.351 |
| High-dose antipsychotic medication, n (%) | 734 (19.6) | 250 (22.5) | 484 (18.4) | χ2 = 8.523 | 0.004 | 0.126 |
| First-generation antipsychotics, n (%) | 1428 (38.1) | 481 (43.3) | 947 (36.0) | χ2 = 18.029 | <0.0001 | 0.043 |
| Second-generation antipsychotics, n (%) | 3126 (83.4) | 922 (83.1) | 2204 (83.7) | χ2 = 0.212 | 0.645 | 0.194 |
| Olanzapine, n (%) | 761 (20.3) | 236 (21.3) | 525 (19.9) | χ2 = 0.852 | 0.356 | 0.079 |
| Clozapine, n (%) | 691 (18.5) | 201 (18.1) | 490 (18.6) | χ2 = 0.127 | 0.722 | 0.964 |
| Antiparkinson drugs, n (%) | 1400 (37.4) | 322 (29.9) | 1068 (40.5) | χ2 = 37.741 | <0.0001 | <0.0001 |
| Mood stabilizers, n (%) | 526 (14.0) | 217 (19.5) | 309 (11.7) | χ2 = 39.530 | <0.0001 | <0.0001 |
| Antidepressants, n (%) | 384 (10.3) | 86 (7.7) | 298 (11.3) | χ2 = 10.788 | 0.001 | 0.037 |
| Anxiolytics and hypnotics, n (%) | 1185 (31.7) | 398 (35.9) | 787 (29.9) | χ2 = 12.897 | <0.0001 | 0.023 |
| Chlorpromazine equivalent, mean (SD) mg | 570.2 (567.6) | 685.8 (725.9) | 521.5 (477.5) | t = 6.933 | <0.0001 | 0.001 |
| Imipramine equivalent, mean (SD) mg | 14.5 (89.6) | 20.5 (122.9) | 11.9 (70.9) | t = 2.173 | 0.030 | 0.441 |
| Diazepam equivalent, mean (SD) mg | 8.5 (43.4) | 14.7 (71.3) | 5.9 (22.6) | t = 4.010 | <0.0001 | <0.0001 |
| Levodopa equivalent, mean (SD) mg | 45.2 (83.8) | 38.2 (94.3) | 48.2 (78.8) | t = −3.103 | 0.002 | 0.956 |
| Electroconvulsive therapy, n (%) | 165 (4.4) | 50 (4.5) | 115 (4.4) | χ2 = 0.036 | 0.850 | 0.560 |
Adjusted for the effects of age, regional classification, income group, inpatient status, delusions, hallucinations, disorganized behaviors, negative symptoms, social or occupational dysfunction, verbal aggression, physical aggression and significant affective symptoms.
Adverse events in response to psychotropic drug in schizophrenia patients with and without disorganized speech.
| Total sample (n = 3744) | Disorganized speech | Statistical coefficient | Unadjusted | Adjusted | ||
|---|---|---|---|---|---|---|
| Present (n = 1110) | Absent (n = 2634) | |||||
| Rigidity, n (%) | 400 (11.1) | 162 (15.1) | 238 (9.4) | χ2 = 25.118 | <0.0001 | 0.302 |
| Akinesia, n (%) | 220 (6.1) | 102 (9.5) | 118 (4.7) | χ2 = 30.468 | <0.0001 | 0.460 |
| Tremor, n (%) | 666 (18.4) | 275 (25.5) | 391 (15.4) | χ2 = 51.256 | <0.0001 | 0.004 |
| Akathisia, n (%) | 240 (6.7) | 113 (10.5) | 127 (5.0) | χ2 = 36.206 | <0.0001 | 0.003 |
| Dystonia, n (%) | 80 (2.2) | 31 (2.9) | 49 (1.9) | χ2 = 3.097 | 0.078 | 0.831 |
| Constipation, n (%) | 794 (22.1) | 280 (26.1) | 513 (20.4) | χ2 = 14.406 | <0.0001 | 0.203 |
| Excessive salivation, n (%) | 445 (12.3) | 188 (17.5) | 257 (10.2) | χ2 = 37.278 | <0.0001 | <0.0001 |
| Dry mouth, n (%) | 561 (15.5) | 196 (18.2) | 365 (14.4) | χ2 = 8.210 | 0.004 | 0.161 |
| Postural hypotension, n (%) | 162 (4.5) | 68 (6.3) | 94 (3.7) | χ2 = 11.827 | 0.001 | 0.176 |
| Urinating difficulty, n (%) | 93 (2.6) | 51 (4.8) | 42 (1.7) | χ2 = 28.611 | <0.0001 | 0.035 |
| Blurred vision, n (%) | 196 (5.5) | 72 (6.8) | 124 (4.9) | χ2 = 4.801 | 0.028 | 0.972 |
| Sexual dysfunction, n (%) | 204 (6.4) | 80 (8.7) | 124 (5.4) | χ2 = 11.785 | 0.001 | 0.075 |
| Galactorrhea, n (%) | 116 (3.4) | 40 (4.0) | 76 (3.2) | χ2 = 1.516 | 0.218 | 0.152 |
| Impaired glucose tolerance, n (%) | 188 (6.2) | 53 (5.6) | 135 (6.4) | χ2 = 0.671 | 0.413 | 0.875 |
| Hypercholesterolemia, n (%) | 252 (8.5) | 65 (7.2) | 187 (9.1) | χ2 = 2.801 | 0.094 | 0.320 |
| Weight gain, n (%) | 444 (13.2) | 101 (10.5) | 343 (14.3) | χ2 = 8.581 | 0.003 | 0.945 |
| QTc prolongation, | 27 (1.1) | 4 (0.5) | 23 (1.3) | χ2 = 3.806 | 0.051 | 0.048 |
| Oversedation, n (%) | 369 (10.3) | 159 (14.9) | 210 (8.4) | χ2 = 34.083 | <0.0001 | 0.035 |
Adjusted for the effects of age, regional classification, income group, inpatient status, delusions, hallucinations, disorganized behaviors, negative symptoms, social or occupational dysfunction, verbal aggression, physical aggression and significant affective symptoms.
n = 2555.
Binary logistic model for assessing psychotropic drug prescribing patterns and adverse events associated with disorganized speech.
| B | Standard error | Wald | Adjusted | Adjusted odds ratio | 95% confidence interval | |
|---|---|---|---|---|---|---|
| Antiparkinson drugs | −0.391 | 0.093 | 17.658 | <0.0001 | 0.676 | 0.564–0.812 |
| Mood stabilizers | 0.451 | 0.120 | 14.073 | <0.0001 | 1.570 | 1.240–1.986 |
| Diazepam equivalent dose | 0.007 | 0.002 | 21.229 | <0.0001 | 1.007 | 1.004–1.010 |
Adjusted for the effects of age, regional classification, income group, inpatient status, delusions, hallucinations, disorganized or catatonic behavior, negative symptoms, social or occupational dysfunction, verbal aggression, physical aggression and significant affective symptoms.